Author, year/Treatment regimens Wolchok, 2010 1 Robert, 2014 2 Robert, 2015 3 Weber, 2015 4 Hodi, 2017 5 Ascierto, 2017 6 Hamid, 2017 7 Weber, 2017 8 Wolchok, 2017 9 Total Abbreviations: CrI: credible interval; IPI: ipilimumab; N/A: not applicable. Nospecific individual immune-related AE was reported in that treatment regimen in the included studies, so the indirect evidence cannot be generated. (For example, pneumonitis was not reported in any included studies comparing PEM (2 mg/kg/q3 wks) with other treatments, so we cannot generate the indirect evidence of pneumonitis from PEM (2 mg/kg/q3 wks) by linking that with other treatments); NIV: nivolumab; NR: not reportable due to small sample sizes; OR: odds ratio; PEM: pembrolizumab; SD: standard deviations. a We compared posterior means and standard deviations of the log-odds ratios obtained from direct and indirect evidence for each treatment comparison, and then compared the inconsistency as direct effect minus indirect effect at each treatment comparison. b The ratio of the OR indicates ORdirect divied by ORindirect. c P ≤ 0·05 indicates a significant inconsistency between the direct effect and indirect effects. d Immune-related AEs are defined as AEs caused by ICIs, not chemotherapies (i.e., carboplatin, dacarbazine, and paclitaxel). For chemotherapy users, the AEs we identified are chemotherapy-related AEs. eFigure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow Diagram: Literature Search, Study Identification, Selection, and Exclusion Abbreviations: ICIs: immune checkpoint inhibitors; RCT: randomized controlled trial.
